in patients receiving either inhaled or oral glucocorticoids Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with NTM lung disease who have moderate-to-high disease activity despite csDMARD monotherapy This recommendation is based on the lower expected risk of NTM lung disease associated with csDMARDs compared to bDMARDs and tsDMARDs Abatacept is conditionally recommended over other bDMARDs and tsDMARDs for patients with NTM lung disease who